Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$9.65
▲ $0.38 (+4.1%)
Market data updated: 09/20 04:36 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$1.66B
Day Range
$9.08 - $9.74
52-Week Range
$2.24 - $12.06
Beta
—
Next Earnings
10.11.2026
Support
$6.69
Resistance
$11.41
ABSI is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+258.7% (1Y)
Strengths: 16/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Leverage risk
Debt/equity: 0.00
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: -$9.08 vs. price $9.65 (-194.1%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
57
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $9.65
Evidence: Euphoria score crossed 55 (now 55)
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
37
Quality
47
Value
38
Momentum
88
Risk
54
Sentiment
100
Fundamental
34
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Absci Corporation highlights its role as a clinical-stage biopharmaceutical company leveraging generative AI to develop innovative therapeutics. The company is gaining investor attention, particularly for its focus on hair loss treatments alongside broader AI-driven drug discovery efforts. Absci’s participation in investor conferences and its positioning within the rapidly expanding AI-in-drug-discovery market—projected to reach $8.52 billion by 2030—have been key focal points. The company is also noted as part of a growing trend in AI-driven biotech startups attracting Wall Street interest.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Absci Corporation. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
50
🎯 Conviction (vs. Emotion)
36
Psychology
55
Fundamentals
34
Technical
88
Valuation
38
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+30%
Market Narrative
75
Fundamental Reality
36
Narrative Gap
+39
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant herding behavior suggests investors are following peers rather than independent analysis, as ABSI’s -2.7% decline mirrors the sector’s -3.2% drop. Confirmation bias persists due to a widening narrative-reality gap (+39), where positive sentiment (98/100) clashes with weakening fundamentals. Euphoria is muted by negative momentum, while FOMO remains suppressed by lackluster volume and neutral RSI. The key question is whether the narrative gap will narrow or if fundamentals deteriorate further, potentially shifting behavior from herd alignment to selective reassessment.
Updated: 09/09/2026, 02:52 PM
What could change this?
👥 What the crowd believes
"Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI"
"Hair loss biotechs Veradermics, Absci, and Cosmo are drawing investor bets on a market untouched since the 1990s"
"The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci"
"Absci Corporation... today announced the company will be participating in the following upcoming investor conferences"
🧠 Market Brain events driving this
📈 18D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Philip Fisher — 7/100
🗣️ Why do they disagree?
Based on Walter Bagehot’s documented focus on liquidity, the model estimates a perfect score of 100, indicating the stock would likely survive a credit squeeze, whereas most value‑oriented investors such as Graham (60) and the Enterprising Graham variant (44) find the stock only marginally meets their safety margins. Growth‑oriented thinkers like Thorstein Veblen (65) see alignment with real value creation, but Peter Lynch (36) and Philip Fisher (7) deem the growth‑at‑a‑reasonable‑price and quality criteria unmet. Momentum and risk‑focused frameworks—from Marks (35) to Mackay (32) and the market‑cycle view of Marks (31)—highlight late‑cycle or crowd‑delusion concerns, leading to cautionary verdicts. Meanwhile, technical and systematic approaches like those of Livermore (61), Loeb (57), Schwager (38) and the efficient‑market view (42) produce mixed or neutral signals, reflecting their emphasis on trend, risk, and index‑relative performance rather than absolute fundamentals.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 67
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 65
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 60
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 57
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 41
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 40
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 38
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 36
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 35
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 31
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 25
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 11
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 7
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 1 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-4297.0%
Net Margin
-4113.7%
EBITDA Margin
—
ROE
-60.8%
ROA
-53.3%
ROIC
—
EPS
-$0.84
Cash
$20.02M
Total Debt
—
Current Ratio
6.57
Debt/Equity
0.00
How is Fair Value calculated? →
Current Price
$9.65
Estimated Fair Value (DCF)
-$9.08
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-194.1%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
-5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -5.0% | $-89.33M | $-81.95M |
| 2 | -3.1% | $-86.54M | $-72.84M |
| 3 | -1.2% | $-85.46M | $-65.99M |
| 4 | 0.6% | $-85.99M | $-60.92M |
| 5 | 2.5% | $-88.14M | $-57.29M |
Base FCF (last actual year)
$-94.03M
Terminal Value
$-1.39B
Present Value of Terminal Value
$-903.35M
Enterprise Value
$-1.24B
Net Debt
$0
Equity Value
$-1.24B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$1.25
Tangible Book Value per Share (Tangible NAV)
$0.98
Sentiment based on basic keywords (not AI) — 10 positive, 9 neutral, 1 negative out of the last 20 articles.
Benzinga · 17.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 12.9.2026
Insider Monkey · 12.9.2026
Benzinga · 11.9.2026
SeekingAlpha · 9.9.2026
SeekingAlpha · 8.9.2026
Benzinga · 8.9.2026
Yahoo · 3.9.2026
CNW Group · 3.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
Yahoo · 31.8.2026
BeInCrypto · 31.8.2026
SeekingAlpha · 20.8.2026
Motley Fool · 19.8.2026
24/7 Wall St. · 18.8.2026
Zacks · 18.8.2026
Zacks · 17.8.2026
MarketBeat · 17.8.2026
Absci Corporation (ABSI) currently has a StockIQ AI score of 57/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ABSI currently scores 57/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ABSI's estimated fair value is -$9.08, which is 194.1% below the current price of $9.65. This is one valuation model among several signals in the fair-value category, not a price target.
ABSI's technical score is 88/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Debt/equity: 0.00; Current ratio: 6.57; Price is above the 50-day average.
Based on the real signals StockIQ computed: Estimated fair value: -$9.08 vs. price $9.65 (-194.1%); Operating margin: -4297.0% (negative); Net margin: -4113.7% (negative).
StockIQ has no recorded dividend payment history for ABSI.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Jonasson Zachariah | Tax Withholding in Shares | 31.8.2026 | 8,320 | -8,320 | $8.71 |
| Somaratne Ransi Mudalinayake | Grant/Award from Employer | 3.8.2026 | 383,000 | +383,000 | — |
| Somaratne Ransi Mudalinayake | Grant/Award from Employer | 3.8.2026 | 383,000 | +383,000 | — |
| Szela Mary T | Open Market Purchase | 30.6.2026 | 12,900 | +12,900 | $11.54 |
| Szela Mary T | Open Market Purchase | 30.6.2026 | 21,300 | +12,900 | $11.54 |
| McClain Sean | Tax Withholding in Shares | 24.6.2026 | 59,896 | -59,896 | $10.08 |
| McClain Sean | Tax Withholding in Shares | 24.6.2026 | 8,655,555 | -59,896 | $10.08 |
| Sirosh Joseph | Grant/Award from Employer | 4.6.2026 | 39,800 | +39,800 | — |
| Rabinovitsj Daniel A | Grant/Award from Employer | 4.6.2026 | 39,800 | +39,800 | — |
| Sirosh Joseph | Grant/Award from Employer | 4.6.2026 | 10,100 | +10,100 | — |
| Rabinovitsj Daniel A | Grant/Award from Employer | 4.6.2026 | 10,100 | +10,100 | — |
| VAN HOUTEN FRANS | Grant/Award from Employer | 4.6.2026 | 39,800 | +39,800 | — |
| VAN HOUTEN FRANS | Grant/Award from Employer | 4.6.2026 | 10,100 | +10,100 | — |
| Pangalos Menelas N | Grant/Award from Employer | 4.6.2026 | 39,800 | +39,800 | — |
| Pangalos Menelas N | Grant/Award from Employer | 4.6.2026 | 10,100 | +10,100 | — |
| Szela Mary T | Grant/Award from Employer | 4.6.2026 | 39,800 | +39,800 | — |
| MCGINNIS KAREN K | Grant/Award from Employer | 4.6.2026 | 10,100 | +10,100 | — |
| Szela Mary T | Grant/Award from Employer | 4.6.2026 | 10,100 | +10,100 | — |
| MCGINNIS KAREN K | Grant/Award from Employer | 4.6.2026 | 39,800 | +39,800 | — |
| Rabinovitsj Daniel A | Grant/Award from Employer | 4.6.2026 | 33,420 | +10,100 | — |
| Rabinovitsj Daniel A | Grant/Award from Employer | 4.6.2026 | 39,800 | +39,800 | — |
| Szela Mary T | Grant/Award from Employer | 4.6.2026 | 10,100 | +10,100 | — |
| Szela Mary T | Grant/Award from Employer | 4.6.2026 | 39,800 | +39,800 | — |
| Sirosh Joseph | Grant/Award from Employer | 4.6.2026 | 33,420 | +10,100 | — |
| Sirosh Joseph | Grant/Award from Employer | 4.6.2026 | 39,800 | +39,800 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
36,788,063 shares short as of 2026-08-31 · vs. 37,308,520 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
43.1% of trading volume this week was short selling, vs. 43.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology